Finance

Lists
Q3 2026 earnings • released • EPS miss -17.27%
See results
SGP:NASDAQ
SpyGlass Pharma Inc
$32.88
-1.32%
(-0.44) 1D
Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SGP...
Open
$33.88
High
$33.88
Low
$32.12
Mkt. cap
1.10B
Avg. vol.
103.27K
Volume
39.46K
52-wk high
$39.92
52-wk low
$17.06
EPS
-$2.43
No. of employees
76
Open
$33.88
High
$33.88
Low
$32.12
Mkt. cap
1.10B
Avg. vol.
103.27K
Volume
39.46K
52-wk high
$39.92
52-wk low
$17.06
EPS
-$2.43
No. of employees
76
News stories
From web sources and news partners
About SpyGlass Pharma Inc
CEO-
Employees76
Founded2019
HeadquartersAliso Viejo, California, United States
SectorHealth Care
IndustryPharmaceutical industry
Websitespyglasspharma.com
Analyst ratings
Based on 5 analysts giving stock ratings to SGP in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for SGP in the last 3 months.
Highest
Current $32.88
$45.00 (+36.86%)
Average
$43.60 (+32.60%)
Lowest
$42.00 (+27.74%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Leerink Partners
Buy
Maintained
$42.00
+27.7%
11/13/2026
Thomas Stephan
Stifel Nicolaus
Buy
Maintained
$44.00
+33.8%
11/13/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$45.00
+36.9%
11/13/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
$43.00
+30.8%
11/13/2026
Christopher Raymond
Raymond James
Buy
Maintained
$44.00
+33.8%
11/12/2026
Dennis Ding
Jefferies
Buy
Maintained
$62.00
+88.6%
05/19/2026
Marc Goodman
Leerink Partners
Buy
Initiated
$42.00
+27.7%
03/03/2026
Last report
Nov 12, 2026
Fiscal period
Q3 2026
-$0.73 / -$0.62
-17.27%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
7.71M
8.54M
10.94M
10.03M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.92M
6.87M
11.02M
16.21M
Operating expense
13.63M
15.41M
21.97M
26.24M
Total operating expenses
13.63M
15.41M
21.97M
26.24M
Operating income
-13.63M
-15.41M
-21.97M
-26.24M
Other non operating income
11.00
-
-
-
EBT including unusual items
-12.56M
-13.82M
-19.86M
-24.25M
EBT excluding unusual items
-12.56M
-13.82M
-19.86M
-24.25M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12.56M
-13.82M
-19.86M
-24.25M
Net profit margin
-
-
-
-
Earnings per share
-
-0.69
-0.59
-0.73
Interest and investment income
1.07M
1.59M
2.10M
1.99M
Interest expense
-
-
-
-
Net interest expenses
1.07M
1.59M
2.10M
1.99M
Depreciation and amortization charges
-
-
-
-
EBITDA
-13.41M
-15.09M
-21.62M
-25.90M
Gain or loss from assets sale
1.10K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps